Singulair Linked to Mental Health Risks
-
December 14, 2024
-
KBA Attorneys
-
No Comments
Popular Asthma Drug Singulair Linked to Mental Health Risks, Including Suicides
Mounting evidence suggests that Singulair (montelukast), a once widely praised asthma and allergy medication, may be linked to severe mental health issues. These issues may include suicidal thoughts and behaviors. Our drug lawyers are investigating Singulair mental health matters.
Singulair (montelukast): Background Information
Singulair (generic name: montelukast) is a prescription medication primarily used to manage and prevent asthma symptoms and treat seasonal or perennial allergic rhinitis (hay fever). It works by blocking leukotrienes—chemical substances in the body that cause inflammation, swelling, and constriction in the airways. This action helps reduce asthma attacks, improve breathing, and alleviate allergy symptoms such as sneezing, runny nose, and itchy or watery eyes.
The drug was approved by the FDA in 1998 and became widely popular, especially for its convenience as an oral tablet. It is often prescribed to adults and children aged 12 months and older, making it a common choice for pediatric asthma and allergy management. In some cases, Singulair is also used to prevent exercise-induced bronchoconstriction (narrowing of airways).
Singulair May Have Alarming Side Effects, Linking Singulair Mental Health
According to new FDA research presented at a toxicology meeting based on a recent study, the drug binds to brain receptors involved in mood regulation. This may be the Singulair mental health link.
This mechanism of action potentially causes neuropsychiatric side effects such as anxiety, depression, hostility, and even suicide. These findings build on earlier reports of the drug penetrating brain tissues in animals. This story broke earlier this year, and can be found here:
Because of these concerns, the FDA announced a Safety Communication and Black Box Warning in 2020 after years of reported mental health side effects. The label advises limiting its use to patients with no other treatment options, yet the drug remains widely prescribed to both adults and children. However, the label has not been updated since 2020, while new mounting evidence continues to come out. Thus the Singulair mental health link may be understated.
Since its launch in 1998, Singulair has been associated with thousands of reports of neuropsychiatric issues and dozens of suicides, sparking backlash against its manufacturers for downplaying early safety concerns. While more research is needed, experts warn the drug is “definitely doing something that’s concerning” in the brain.
Patients experiencing side effects such as worsening mood, confusion, vivid nightmares, or suicidal thoughts should contact their healthcare provider immediately. These findings serve as a reminder of the importance of weighing risks and benefits when considering medication for asthma or allergies.
What This Means For People Using Singulair
We have seen, Singulair ruined my life. For people using Singulair (montelukast) or its generic versions, the emerging evidence raises serious concerns about the drug’s potential impact on mental health. Anyone not already aware of these concerns should raise these issues with their doctor and discuss whether the drug is still a good treatment plan for them, given the 2020 black box warning combined with the news stories on further research that has come out in the past year. While the drug remains a treatment option for asthma and allergies, the link to severe neuropsychiatric side effects—such as anxiety, depression, hallucinations, and suicidal thoughts—means patients and their caregivers need to continually exercise caution and continue to discuss risks and benefits with their doctors.
We Handle Drug Cases
KBA Attorneys are dedicated to helping individuals and families who have suffered serious mental health issues or other adverse effects as a result of taking Singulair (montelukast). If you or a loved one has experienced severe side effects, such as anxiety, depression, or suicidal thoughts, while using this medication, KBA Attorneys can provide a free legal consultation.
We have experience in holding pharmaceutical companies accountable.
Here are some drug cases we currently handle:
- GLP-1 Medications (Ozempic/Wegovy/Trulicity);
- Suboxone;
- Tenofovir (Truvada) (kidney disease and bone injuries);
- Valsartan (liver, kidney, stomach, or intestinal cancer)
If you have taken any of these other drugs/medications, we have written blogs about many of them.
The Potential Dangers of GLP-1 Medications
Multidistrict Litigation (MDL) Related to Suboxone Film Products
Mylan Pharmaceuticals Expands Recall For Valsartan Drugs
KBA is Dedicated to People Affected by Harmful Drugs and Medical Devices
Our team works hard to investigate the drug’s manufacturers. We explore why the company failed to provide a safe drug to their consumers. This includes looking at failing to adequately warn patients about these risks, cutting corners, and failing to prioritize profits over safety. We investigate claims of defective drug design, manufacturing errors, and inadequate warnings about potential side effects. This dedication involves collaborating with medical experts, analyzing scientific data, and pursuing justice for those injured. Our goal is to ensure that manufacturers take responsibility for their actions and that affected individuals receive compensation for medical costs, emotional distress, and other damages. By holding these companies accountable, we not only advocate for victims but also push for higher standards of safety in the pharmaceutical industry.
We Understand The Physical and Emotional Toll of Harmful Drugs
Contact us (KBA Attorneys) today to discuss your case and explore your legal options. Attorneys Robert Price and Keith Smith have vast experience litigating drug cases. Partner Robert E. Price leads KBA’s largest drug and device litigations. He has a history of trying pharmaceutical device and drug cases and was a trial team member in a historic drug trial that resulted in a $9 Billion dollar verdict. (In Re: Actos (Pioglitazone) Products Liability Litigation (MDL 2299); Allen v. Takeda Pharmaceuticals.) His work secured over $100 Million dollars in recoveries on behalf of injured clients in his first 7 years of practice alone. Mr. Price is investigating the Singulair mental health link.
We will fight to secure compensation for medical expenses, emotional distress, and other damages caused by the medication’s harmful effects.
KBA Attorneys get how tough it can be when a medication you trusted ends up causing more harm than good. We understand the stress, the fear, and the emotional toll it takes—not to mention the medical bills and other costs that can pile up. When a drug causes serious side effects, it’s not just about the physical pain; it’s about the way it affects your whole life, from your health to your relationships. That’s why we’re here to help. We’ll fight to make sure the company responsible is held accountable and that you get the support you need to cover those costs and start moving forward. You shouldn’t have to face this alone, and we’re ready to stand with you.